Profile data is unavailable for this security.
About the company
Biocon Limited is an India-based biopharmaceutical company, which focuses on treating diabetes, cancer and autoimmune diseases. Its segment includes Generics, Biosimilars, Novel Biologics and Research Services. It has developed and commercialized novel biologics, biosimilars, and complex small molecule active pharmaceutical ingredients (APIs) in India and several key global markets, as well as Generic Formulations in the United Sates, Europe and key emerging markets. Its API portfolio includes cardiology, anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology and other key products. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. It has over five facilities across Bangalore, Hyderabad and Visakhapatnam in India. Its API manufacturing facilities leverage complex technology platforms that range from microbial fermentation, chromatographic purification, chemical synthesis, peptide synthesis and HPAPIs.
- Revenue in INR (TTM)147.66bn
- Net income in INR15.81bn
- Incorporated1978
- Employees3.68k
- LocationBiocon Ltd20th KM, Hosur Road, Electronic City,BANGALORE 560100IndiaIND
- Phone+91 8 028082808
- Fax+91 8 028523423
- Websitehttps://www.biocon.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Peptidream Inc | 31.41bn | 12.29bn | 210.64bn | 603.00 | 17.10 | 6.30 | 15.45 | 6.71 | 167.15 | 167.15 | 427.44 | 453.44 | 0.7217 | 4.49 | 2.97 | 91,906,740.00 | 28.25 | -- | 33.81 | -- | 77.98 | -- | 39.14 | -- | 3.23 | 14.72 | 0.2626 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
Dizal Jiangsu Pharmaceutical Co Ltd | 3.53bn | -11.23bn | 217.96bn | 581.00 | -- | 29.91 | -- | 61.78 | -2.29 | -2.29 | 0.7174 | 1.47 | 0.1742 | 0.4174 | 4.62 | 507,467.80 | -60.62 | -46.02 | -81.84 | -52.99 | 96.75 | 57.53 | -347.91 | -2,081.54 | 1.81 | -- | 0.5253 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
Sinocelltech Group Ltd | 28.53bn | -1.59bn | 220.42bn | 2.33k | -- | -- | -- | 7.73 | -0.2974 | -0.2974 | 5.35 | -1.03 | 0.818 | 0.4037 | 5.81 | 1,021,836.00 | -4.55 | -40.17 | -13.68 | -74.63 | 96.26 | 95.42 | -5.56 | -108.20 | 0.5057 | 4.62 | 1.19 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
Shanghai Allist Pharmaceuticals Co Ltd | 34.06bn | 13.07bn | 297.15bn | 1.04k | 22.74 | 5.50 | -- | 8.72 | 2.43 | 2.43 | 6.32 | 10.03 | 0.6579 | 3.28 | 10.58 | 2,726,042.00 | 25.24 | 0.6405 | 27.43 | 0.6933 | 94.47 | 96.42 | 38.37 | 2.54 | 7.88 | -- | 0.0003 | 211.88 | 155.14 | 237.34 | 393.54 | -- | 13.53 | -- |
Genscript Biotech Corp | 84.80bn | -14.87bn | 334.30bn | 7.28k | -- | 3.27 | -- | 3.94 | -0.6495 | -0.6495 | 3.71 | 4.44 | 0.3006 | 9.15 | 7.99 | 1,130,268.00 | -9.68 | -18.34 | -14.76 | -26.15 | 53.63 | 54.68 | -32.19 | -64.91 | 4.06 | -- | 0.1972 | -- | 34.17 | 29.44 | 57.91 | -- | 17.14 | -- |
Syngene International Ltd | 34.70bn | 4.92bn | 348.42bn | 6.51k | 71.00 | -- | 37.75 | 10.04 | 12.24 | 12.24 | 86.29 | -- | -- | -- | -- | 5,330,569.00 | -- | 8.62 | -- | 11.43 | 72.89 | 71.13 | 14.19 | 16.22 | -- | 7.57 | -- | -- | 9.26 | 13.83 | 9.82 | 8.99 | -2.62 | 20.11 |
Telix Pharmaceuticals Ltd | 36.65bn | 2.79bn | 389.21bn | 234.00 | 136.87 | 16.95 | 121.52 | 10.62 | 0.1497 | 0.1497 | 1.96 | 1.21 | 1.22 | 11.36 | 8.61 | -- | 9.31 | -29.08 | 15.01 | -40.27 | 61.80 | 61.64 | 7.62 | -37.14 | 0.8687 | -- | 0.052 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
Biocon Ltd | 147.66bn | 15.81bn | 407.07bn | 3.68k | 25.75 | -- | 11.22 | 2.76 | 13.20 | 13.20 | 123.37 | -- | -- | -- | -- | 40,114,100.00 | -- | 3.20 | -- | 4.48 | 67.01 | 62.04 | 13.62 | 9.37 | -- | 1.54 | -- | 8.22 | 32.05 | 21.76 | 120.99 | 2.46 | 5.30 | 0.00 |
Sichuan Kelun-Biotech Biophrmctcl Co Ltd | 22.47bn | -2.79bn | 521.55bn | 1.54k | -- | 13.58 | -- | 23.21 | -1.14 | -1.14 | 9.39 | 15.94 | 0.5869 | 9.46 | 167.74 | 1,468,051.00 | -7.28 | -- | -16.56 | -- | 61.81 | -- | -12.40 | -- | 5.59 | -- | 0.0118 | -- | 91.62 | -- | 6.81 | -- | -- | -- |
PharmaEssentia Corp | 18.05bn | 3.46bn | 558.43bn | 131.00 | 153.28 | 8.22 | 128.39 | 30.95 | 4.09 | 4.09 | 21.42 | 76.26 | 0.2478 | 0.6845 | 4.22 | -- | 4.75 | -16.79 | 5.08 | -19.66 | 87.46 | 76.47 | 19.16 | -79.56 | 12.10 | -- | 0.0408 | -- | 77.15 | 186.97 | 54.62 | -- | 66.34 | -- |
Holder | Shares | % Held |
---|---|---|
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2024 | 59.25m | 4.94% |
SBI Funds Management Ltd.as of 31 Jul 2024 | 32.67m | 2.72% |
Arohi Asset Management Pte Ltd.as of 17 Mar 2023 | 18.95m | 1.58% |
Kotak Mahindra Asset Management Co. Ltd.as of 30 Jun 2024 | 18.75m | 1.56% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 17.26m | 1.44% |
Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Jul 2024 | 9.25m | 0.77% |
BlackRock Fund Advisorsas of 04 Jul 2024 | 5.97m | 0.50% |
ICICI Prudential Asset Management Co. Ltd.as of 31 Jul 2024 | 5.90m | 0.49% |
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jul 2024 | 5.05m | 0.42% |
Tata Asset Management Pvt Ltd.as of 31 Jul 2024 | 4.61m | 0.38% |